Key result
The ABCB1 C3435T polymorphism showed a non-significant trend toward a higher risk of adverse cardiovascular events in clopidogrel-treated patients carrying the wild-type C allele (OR 1.306, p=0.35855).
Observational (n=203)
No
Odds Ratio: 1.306
Absolute Event Rate: 0.5568% vs 0.4904%
p-value: p=0.35855
ABCB1 C3435T may affect clopidogrel response post-PCI; leaves open whether genotyping improves outcomes.
Background: Clopidogrel has been used as a gold standard (alone or in association with aspirin) to prevent vascular complications in atherothrombotic patients undergoing PCI, and as a long-term prevention of cardiovascular events. The drug is subject to efflux via P-glycoprotein (encoded by the ABCB1 gen, also known as MDR1). The ABCB1 C3435T polymorphism may be associated with altered drug metabolism, efficacy and clinical outcome. The aim of this study was to evaluate the influence of ABCB1 C3435T genotype on clinical cardiovascular outcomes in coronary artery disease patients on clopidogrel treatment.
No takes yet. Share an insight, caveat, or question.
Vavlukis et al. (2017) conducted an observational in Coronary artery disease (n=203). ABCB1 C3435T genotype (C allele) vs. T allele was evaluated on Major adverse cardiovascular events (MACE) (OR 1.306, p=0.35855). The ABCB1 C3435T polymorphism showed a non-significant trend toward a higher risk of adverse cardiovascular events in clopidogrel-treated patients carrying the wild-type C allele (OR 1.306, p=0.35855).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: